Bellerophon Therapeutics Inc. (NASDAQ: BLPH) stock closed at 0.4076 per share at the end of the most recent trading day (a -1.04% change compared to the prior day closing price) with a volume of 8.83K shares and market capitalization of 4.99M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 18 people. Bellerophon Therapeutics Inc. CEO is Fabian Tenenbaum.

The one-year performance of Bellerophon Therapeutics Inc. stock is -62.72%, while year-to-date (YTD) performance is -54.71%. BLPH stock has a five-year performance of -97.7%. Its 52-week range is between 0.37 and 12.58, which gives BLPH stock a 52-week price range ratio of 0.31%

Bellerophon Therapeutics Inc. currently has a PE ratio of -1.20, a price-to-book (PB) ratio of 3.12, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -97.54%, a ROC of -109.85% and a ROE of -130.39%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Bellerophon Therapeutics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Bellerophon Therapeutics Inc.’s next earnings report date is 13th Nov 2023.

The consensus rating of Wall Street analysts for Bellerophon Therapeutics Inc. is — (0), with a target price of $24.5, which is +5 910.79% compared to the current price. The earnings rating for Bellerophon Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bellerophon Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Bellerophon Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 7.70, ATR14 : 0.04, CCI20 : -79.33, Chaikin Money Flow : 0.14, MACD : -0.03, Money Flow Index : 49.36, ROC : -9.42, RSI : 39.18, STOCH (14,3) : 40.16, STOCH RSI : 0.63, UO : 43.15, Williams %R : -59.84), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bellerophon Therapeutics Inc. in the last 12-months were: Bobae Kim (Option Excercise at a value of $9 620), Bobae Kim (Sold 9 455 shares of value $94 550 ), Life Science Opportunities Fund Vi Puissance (Sold 694 421 shares of value $5 409 169 ), Martin Dekker (Option Excercise at a value of $0), Nicholas Laccona (Option Excercise at a value of $0), Parag Shah (Option Excercise at a value of $0), Peter Fernandes (Option Excercise at a value of $0), Puissance Life Science Opportu (Sold 134 421 shares of value $111 569 )